Latest Breaking News On - Eva kalias - Page 9 : comparemela.com

Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 27, 2023, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from. | April 27, 2023

United kingdomSwitzerland generalUnited statesShabir hashamAndrew smithEva kaliasBradley meyerDario eklundSanthera pharmaceuticals holding ltdEuropean commissionChiesi groupEuropean medicines agencyStrategy committeeAdvisory committee meetingLife science allianceSanthera pharmaceuticals holding

Santhera Pharmaceuticals Holding AG: Vamorolone NDA mid-cycle review meeting by FDA completed

Pratteln, Switzerland, and Rockville, MD, USA, April 25, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting

United statesSwitzerland generalUnited kingdomEric hoffmanEva kaliasShabir hashamReveragen biopharmaEuropean medicines agencySanthera pharmaceuticals holdingDrug administrationRegulatory agencyNational institutes of healthUs department of defenseReveragen biopharma incDuchenne research fundHead investor relations communications

Santhera Pharmaceuticals Holding AG: Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy

Pratteln, Switzerland, March 2, 2023 - Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare products Regulatory

Switzerland generalUnited statesUnited kingdomDennis riedlShabir hashamEric hoffmanEva kaliasReveragen biopharmaLife science allianceSanthera pharmaceuticalsMuscular dystrophy association united statesNational institutes of healthDuchenne research fundFoundation to eradicate duchenneDrug administrationRegulatory agency

Santhera Secures Additional Funding Through a Private Placement of Shares and Upsizing of Existing Financing Arrangement

Santhera Secures Additional Funding Through a Private Placement of Shares and Upsizing of Existing Financing Arrangement
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalUnited statesHoulihan lokeyEva kaliasBradley meyerThomas meierJonathan segalDario eklundSanthera pharmaceuticals switzerlandStrategy committeeSantherawillforma strategy committeeSanthera pharmaceuticals schweizSanthera pharmaceuticals holdingHarvard universityHead investor relations communicationsSanthera pharmaceuticals

Santhera Pharmaceuticals Holding AG: Santhera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolone

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, February 8, 2023 - Santhera Pharmaceuticals (SIX: SANN) announces that it has secured a final reimbursement agreement with the

Switzerland generalUnited statesEva kaliasDario eklundSchwierige zeitenRaxone to chiesi groupSanthera pharmaceuticalsHead investor relations communicationsEuropean medicines agencyChiesi groupSanthera pharmaceuticals holdingFrom augustNorth americaHead investor relations